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Abstract
Glucocorticoid-induced TNF receptor (GITR) plays a crucial role in modulating immune response and
inflammation, however the role of GITR in human cancers is poorly understood. In this study, we
demonstrated that GITR is inactivated during tumor progression in Multiple Myeloma (MM) through
promoter CpG island methylation, mediating gene silencing in primary MM plasma cells and MM cell
lines. Restoration of GITR expression in GITR deficient MM cells led to inhibition of MM proliferation in
vitro and in vivo and induction of apoptosis. These findings were supported by the presence of
induction of p21 and PUMA, two direct downstream targets of p53, together with modulation of NF-κB
in GITR-overexpressing MM cells. Moreover, the unbalanced expression of GITR in clonal plasma cells
correlated with MM disease progression, poor prognosis and survival. These findings provide novel
insights into the pivotal role of GITR in MM pathogenesis and disease progression.
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Introduction
Tumor Necrosis Factor receptor superfamily
members (TNFRSFs) play an important role in immune
responses and inflammatory reactions [1–5]. It has
been recently shown that TNFRSFs are also associated
with the pathogenesis of Multiple Myeloma (MM) [6,7].
For example, CD40 (TNFSF5) mediates MM cell survival
and proliferation, as well as migration through the NF-
κB pathway [8]. Other members of the family such as
APRIL (TNFRSF13B) and BAFF (TNFRSF17) were shown
to be involved in the protection of MM cells from
apoptosis via NF-κB activation [9], while loss-of-
function mutations of Fas antigen (TNFRSF6) could
inhibit Fas ligand induced apoptosis in MM cells [10].
These studies suggest that TNFRSFs could play multiple
roles in the pathogenesis of MM. Glucocorticoid-
induced TNFR-related gene (GITR) is a member of the
TNFR super family (TNFRSF18) that is considered a key
regulator in a multitude of immune functions. GITR is
expressed and further upregulated on most immune
cell types like regulatory T cells (T-regs), naïve T cells
and natural killer cells (NKs) [11]. GITR plays a pivotal
role in inflammation processes and autoimmune
diseases. It is triggered by its ligand (GITRL), mainly
expressed in antigen-presenting cells and endothelial
cells [12]. Conversely, GITR engagement in NK cells
induces an inhibitory effect, even though a separate
study provides opposite results, demonstrating that co-
stimulation by GITR/GITRL interaction is found either to
activate or to inhibit NK cells [13,14]. GITR expression
in tumor infiltrating lymphocytes has been found to be
associated with cancer progression in patients suffering
from esophageal adenocarcinomas. However, the role
of GITR as a direct regulator of tumor progression in
MM has not been previously described.
Multistep tumor progression occurs as a succession
of clonal expansions, which is triggered by acquisition
of an enabling mutant genotype. Clonal expansion may
occur due to acquired mutations or epigenetic
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alterations such as DNA methylation and histone
modifications affecting the regulation of gene
expression. In general, cancers are characterized by a
global DNA hypomethylation and locus-specific
hypermethylation of tumor suppressor genes.
In this study, we demonstrated that GITR is
inactivated during tumor progression in MM through
promoter CpG island methylation, mediating gene
silencing in primary MM plasma cells and MM cell lines.
Restoration of GITR expression in GITR deficient MM
cells led to inhibition of MM proliferation in vitro and in
vivo and induction of apoptosis. Notably, GITR/GITRL
interaction increased the level of p53-regulated genes,
such as CDKN1A (p21) and BBC3 (PUMA) in a ligand
dependent manner. Mechanistically, we demonstrated
that GITR negatively regulates the NF-κB signaling
pathway in MM cells leading to apoptosis in response to
TNF-α. These findings imply that GITR acts as a
potential tumor suppressor gene in MM, and its
epigenetic silencing facilitates NF-κB activation and
tumor proliferation in MM.
Materials and Methods
Ethics statement
Bone marrow samples from patients with MM were
obtained under Dana-Farber Cancer Institute IRB
approval with written informed consent and according
to the declaration of Helsinki. In in vivo studies, mice
were treated, monitored, and sacrificed in accordance
with approved protocol of the Dana-Farber Cancer
Institute Animal Care and Use Committee.
Cultured cell lines and primary tumor samples
Five human myeloma cell lines were used: MM1.S,
U266, RPMI (ATCC, Manassas, VA); OPM1 and INA6
(kind gift of Dr. K. Anderson, Dana-Farber Cancer
Institute, Boston, MA) (15). Cells were cultured in
RPMI1640 medium with 10% FBS. The umbilical vein
endothelial HUVEC cell line (Cambrex, Walkersville,
MD) was cultured in EGM-2 MV media (Cambrex)
reconstituted according to the manufacturer. Plasma
cells from patients with multiple myeloma were
obtained using anti-human CD138 microbead selection
(Miltenyi Biotec, Auburn, CA). GFP+/GITR+ MM.1S cells
were generated using lentivirus based transfection
approach.
Methylated DNA immunoprecipitation (MeDIP)
assay
25 mg of gDNA sample were diluted in TE buffer (10
mMTris-HCl, pH 7.5, 1 m MEDTA) and sheared to
between 300 to 800 bp. 4 µg DNA of each sample was
saved as input and the rest heated to 95°C for 10 min
and immediately placed on ice. Immunoprecipitation
was performed using 10 µg anti-5MeCyt monoclonal
antibody for (Eurogentec, Bi-MECY-0100) sheared gDNA
in IP buffer (20 mM Na-Phosphate, pH 7.0, 1 M NaCl,
2% Triton-X100). MeDIP was purified and precipitated
using phenol and chloroform: isoamyl alcohol. The
extent of methylated DNA enrichment in our MeDIP
samples was verified by qPCR on an Applied
Biosystems 7500 Real-Time PCR System using the
following primers:
TNFRSF18F: 5’-TTCAAGAGCCCACAGCCAGTTG-3’
TNFRSF18R: 5’-ATTCTCAGGTCATGAACGGTCCC-3’.
TNFRSF11AF: 5’-GAGTTTTGGGGAGCGGAGGC-3’
TNFRSF11AR: 5’-GTTATCTGCCGCAAGTGAGG-3’
TNFRSF9F: 5’- CATTGAGCAGCTGGAGAACCTC-3’
TNFRSF9R: 5’-CGTCCGCATCTGTCCGCATC-3’
TNFRSF19F: 5’- CACTCATCCGCTTCAGTAGCC -3’
TNFRSF19R: 5’- GCACACCGTGCACCTCCCAG-3’
TNFRSF21F: 5’-GAGAGGTCCCCATGGCTGAAC-3
TNFRSF21R: 5’- GTGCTGAGCGCCCCTAGAGC-3’
TNFRSF8F: 5’- GCTGGGACTGATTCATTCATTC-3’
TNFRSF8R: 5’- CGGACGACCAACCTCCCATG-3’
TNFRSF11BF: 5’- CTTACCACGAGCGCGCAGC-3’
TNFRSF11BR: 5’-CTGATCAAAGGCAGGCGATAC-3’
The relative changes in the extent of promoter
methylation were determined by measuring the
amount of promoter in immunoprecipitated DNA after
normalization to the input DNA %(MeDNA-IP/Input) =
2^[(Ct(input)-Ct(MeDNA-IP) ×100.
Bisulfite sequencing and methylation specific
PCR.  Genomic DNA was prepared and bisulfite
converted by EpiTect Plus DNA Bisulfite Kit (Qiagen,
Valencia, CA). PCR products were purified and cloned
into PGEM-T-easy vector (Promega, San Luis Obispo,
CA), then sent for DNA automatic sequencing. Primer
sequences for GITR are Forward 5’-
GGGTTATTGGTTGGAGTTGGTAT-3’, reverse 5’-
CCTATCCCCATTCTATAAAATTCC-3’. Primer sequences
for MSP are
MF: 5’- GCGGCAGCAGCGCGTCGTGTGAACCCG-3’,MR:
5’- CGCGTTTCGAACCCTATACGA-3’UF: 5’-
GTGGTAGTAGTGTGTTGTGTGAACCTG-3’UR: 5’-
CACATTTCAGGCCCTGTGCAG-3’
Bone marrow Tissue
Immunohistochemistry.  Bone marrow tissues were
obtained from both healthy individuals and MM
patients. Samples were embedded in paraffin-
decalcified in Rapid-Cal-Immuno (BBC, Stanwood, WA)
for 1 hour, washed, and then paraffin embedded. For
GITR staining, 3- to 4-μm tissue sections were mounted
on plus slides, dried for 2 hours in a 60°C oven, and
then stained using GITR polyclonal antibody (R&D
system, Minneapolis, MN, cat# AF689; 1:200 dilution)
according to established protocols in a BenchMark
automated immunostainer (Ventana Medical Systems,
Tucson, AZ). Heat-induced epitope retrieval was
performed with the EDTA-buffered cell conditioning
(CC1) retrieval solution. Immunostaining was
completed with the iView diaminobenzidine
tetrahydrochloride (DAB) detection kit (Ventana).
According to the description of GITR antibody,
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immersion fixed paraffin-embedded sections of human
tonsil was subjected to GITR antibody and considered
as positive control.
Lentiviral infection.  PCDH-ef1-CMV-EGFP lentiviral
vector was purchased from SBI Company. cDNA clone
of GITR was purchased from Origene company. cDNA of
GITR was amplified and subcloned into PCDH-ef1-CMV-
EGFP using BamHI and XbaI restriction enzyme sits.
The PCDH-empty control and PCDH-GITR plasmid were
co-transfected with pPACK™ packaging plasmid mix
(SBI, LV050A-1) into 293T cells, which is available in
the frozen stock of the lab. Viral supernatant was
obtained after 72 hrs post-transfection. MM1.S and
OPM1 cell lines were infected by PCDH-control and
PCDH-GITR recombinant lentivirus for 72 hours. Both
GFP positive and GFP negative MM1.S and OPM1 were
sorted by FACS.
Competition assay and cell proliferation
assay.  The GFP competition assay was used to assess
the ability of proliferation of two days after infection.
MM cells were split into replicate wells of 500,000 cells
in 12-well plates. After 24-h treatments with a range of
drug doses, the GFP-positive percentage was quantified
in the surviving cell population by using a BD
Biosciences LSRII flow cytometry. GFP+ and GFP-cells
were sorted and combined as 1:1 ratio. The percentage
of GFP+ cells was examined everyday by flow
cytometry. Proliferation rate and cytotoxicity were
measured by DNA synthesis using BrdU (R&D) assay
and by 3-(4,5-dimethylthiazol-2-yl)-2,5
diphenyltetrazolium bromide (MTT; Chemicon
International, Temecula, CA) dye absorbance,
respectively.
Cell cycle analysis.  For cell cycle analysis by flow
cytometry, cells were seeded in a 10 cm dish at 60%
confluency. The cells were concomitantly treated with
RNase A (Sigma Aldrich, San Luis, MO) and stained with
10ng/ml propidium iodide. Cell cycle status was
determined using a FACS caliber flow cytometer
(Becton Dickinson, Oxford, UK) and analyzed using
FlowJo7.6.5 software.
Immunoblotting.  Whole-cell lysates were subjected
to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to
polyvinyldene fluoride (PVDF) membrane (Bio-Rad
Laboratories, Hercules, CA). The antibodies used for
immunoblotting included anti–caspase3, p-Ikk-β, Ikk-β,
IκB, P65, P50, (Cell Signaling Technology, Danvers,
MA), -p53 and actin (Santa Cruz Biotechnology, Santa
Cruz, CA). Nuclear extracts of the cells were prepared
using the Nuclear Extraction Kit (Panomics, Redwood
City, CA) and subjected to immunoblotting with anti-
p65, -p50/p105, (Cell Signaling Technology, CA), and
anti-nucleolin (Santa Cruz Biotechnology, CA)
antibodies. In addition, the GITR antibody (R&D Cell
Biology, CA) was used for immunoblotting and
immunohistochemistry on tissue microarray sections.
Active Motif for NF-κB activity.  NF-κB activity
was investigated using the Active Motif TransAM NF-κB
Family Kit, a DNA-binding enzyme-linked
immunosorbent assay (ELISA)-based assay (Active
Motif, North America, Carlsbad, CA). Briefly, MM.1S
cells (empty control MM1.S and GITR-transfected
MM1.S) were cultured in presence or absence of TNF-α
(10ng/ml) for 20 minutes. NFκB-p65, -p50 transcription
factors binding to the related consensus sequence on
the plate-bound oligonucleotide were studied from
nuclear extracts, following the manufacturer’s
procedure.
In vivo tumor progression of MM cells.  Seven
SCID mice for each group were injected with 5X106
MM1.S cells. After 4 weeks of tail vein injection, the
bone marrow from the femur and skull, as well as
peripheral blood were isolated from the two groups of
mice. Mice bone marrow tissues were crushed and
filtered into single cell suspension. Anti-human CD138
monoclonal antibody (BD bioscience, San Jose, CA) as
used to examine MM cells growth by both flow
cytometry and immunofluorescence.
Immunofluorescence.  Immunocytochemical
analysis was performed using an epifluorescence
microscope (Nikon Eclipse E800; Nikon, Avon, MA) and
a Photometrics, Cool snap CF color camera (Nikon,
Lewisville, TX). Briefly cells were fixed with 4%
paraformaldehyde in phosphate-buffered saline and
permeabilized with 0.2% Triton X-100. Cells were
blocked in 1X PBS / 5% normal goat serum PBS and
incubated with primary antibody at 4°C overnight. Cells
were incubated with Alexa Fluor 488 goat anti-rabbit
secondary antibody for 2hrs.
cDNA expression profiling.  Total RNA of
control_MM1.S and GITR_MM1.S was isolated using an
RNeasy kit (QIAGEN, Valencia, CA). Quality control of
RNA was done using RNA6000 Nano assay on the
Agilent 2100 Bioanalyzer (Santa Clara, CA).
Hybridization to the Human U133A 2.0 microarray was
performed in Dana-Farber Cancer Institute core facility.
In the experiment comparing the overexpressing GITR
versus empty control, the list of filtered probe-set was
analyzed looking for differentially expressed genes
between experiments (>2-fold change).
Analysis of expression profiling of available
datasets.  GITR expression was analyzed in publicly
available datasets comprising bone marrow plasma
cells from healthy donors (NPC) and different stages of
the MM disease. NPC, MG, US, SMM data was obtained
from GEO dataset GSE5900and MM data from GSE2658
and the MMRC portal (data available at
www.broadinstitute.org/mmgp/home). All the intensity
files were MAS5 transformed and the data was
normalized to the median. Comparisons between two
groups were performed using t-test (2 tailed) and for
more than 2 groups using ANOVA. The comparison of
GITR expression level between molecular MM
subgroups was performed using the two most relevant
Novel role of GITR in Multiple Myeloma
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molecular classifications in MM: the TC and the UAMS
classifications (16,17). Results were considered
significant when p<0.05.
Statistical Analysis.  Statistical significance of
differences in the different groups was determined
using Student’s t-test. The minimal level of significance
was p<0.05. Experiments were repeated in triplicates.
Error bars reported in the figures represent standard
deviations.
Results
GITR is aberrantly methylated in both primary
MM cells and MM cell lines
We hypothesized that deregulation of TNFR super
family members may play a pivotal role in modulating
MM pathogenesis. We therefore evaluated the
expression of TNFRSFs in primary MM cells by
analyzing GEO dataset GSE2658 and found that 7
members of the TNFRSF family includingTNFFSF18
(GITR), TNFRSF11A, TNFRSF9, TNFRSF19, TNFRSF8,
TNFRSF21 and TNFRSF11B exhibited lower expression
levels in MM cells compared to their normal cellular
counterpart (Figure S1a). We next investigated the
mechanisms responsible for down-regulation of
TNFRSFs members; and profiled DNA methylation
status of the promoter CpG islands (CGI) of the related
genes using MeDIP assay in 5 MM cell lines. Primers
were designed within 500bp region around the CpG
islands at the promoter region (Figure 1a). MM cells
presented with significant methylation in the promoter
CGI of GITR (TNFRSF18), with specific higher
methylation in OPM1, MM.1S and U266 cells, compared
to RPMI.8226 and INA6, where lower methylation levels
were documented (Figure 1b). We further confirmed
that hypermethylation of GITR promoter occurred in
MM cells, by performing MeDIP assay using MM1.S and
OPM1 cell lines treated with the demethylating agent,
5’ azacytidine. Untreated cells were used as control,
(Figure S2a).
To further evaluate the methylation status of GITR in
MM cells, we performed methylation-specific PCR (MSP)
for GITR in MM cell line and primary MM bone marrow
CD138+ plasma cells (Figure S2b). The MSP result was
further validated by bisulfate conversion. All the
identified methylated CpG sites were represented as
dark circles, whereas unmethylated sites in that same
region were represented as blank circles across the
entire CpG island (Figure 1.c). Further confirmation was
performed by sanger sequencing (Figure S2.c). Based
on the results of MSP and bisulfate sequencing, we
found that primary clonal plasma cells presented with
promoter GITR methylation in 3 out of the 5 MM
patients studied, compared to the related normal
cellular counterpart, where an unmethylated status
was observed. Notably, primary MM cells and MM cell
lines presented with a similar methylation pattern:
specifically, the hypermethylation was mainly
demonstrated within the first 130 base pairs of CpG
island located at the promoter region In addition, we
found that expression of GITR negatively correlated
with the promoter CGI methylation status, indicating
that loss of GITR expression correlates with aberrant
DNA methylation in MM cells (Figure 1e). These
observation were further confirmed by exposing MM
cells to 5’ azacytidine treatment that led to increase of
GITR levels, both in MM.1S and OPM1 cells (Figure 1d),
while no relatively significant increase of GITR
expression was obtained by performing qPCR in INA6,
U266 and RPMI8226 cell lines, which were
characterized by lower methylation pattern of GITR
promoter (Figure S1d). Furthermore, these data were
also confirmed at protein level; GITR expression
significantly increased upon 5’ azacytidine treatment in
a dose dependent manner, as detected by flow
cytometry (Figure S3b). These findings suggest that
deregulation of GITR may result from an aberrant
promoter CGI methylation in MM cells.
The expression of GITR was next evaluated using
immunohistochemistry in bone marrow specimens of
both MM patients and healthy individuals 82% of the
normal bone marrows evaluated showed GITR
positivity, compared to MM specimens that were GITR
positive only in 33% of the cases (Figure 1e).
Deregulation of GITR correlates with MM
progression, prognosis and survival
We next evaluated the GITR mRNA expression levels
in MM patients-derived CDC138 cells, using publically
available gene expression data sets (GSE5900;
GSE2658); and found a significant reduction of GITR
expression in MM samples, compared to healthy
individuals, and interestingly, we found a sustained
reduced expression of GITR with disease progression,
as shown by comparing MG, US to smoldering MM to
active symptomatic MM patients (Figure 2a; P<0.001).
Further expression analysis was performed in the
subclasses of MM patients, showing that the lowest
expression of GITR was observed in PR group, which
has an advanced and more proliferative form of
myeloma (Fig.2bP < 0.01). We next evaluated the
expression of GITR according to prognosis and survival;
and found that lower expression of GITR correlated with
poor prognosis and survival in MM patients, further
suggesting the functional role of GITR in modulating
MM pathogenesis and disease progression (Figure 2c,
P<0.001; Figure 2d, P 0.03).
Functional role of GITR in MM cells
We next dissected the functional relevance of GITR
expression in modulating MM cell behavior, both in
vitro and in vivo. We performed GFP competition assay
by introducing lentivirus-based vector with GFP labeling
into MM1.S and OPM1 cell lines. Both lenti-CMV-GFP
and lenti-GITR-GFP were selected by flow cytometry
and combined with GFP negative MM cells in 1:1 ratio.
Novel role of GITR in Multiple Myeloma
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Figure 1.  Promoter CpG island Hypermethylation leads to repression of GITR in MM cells.  A) Primer
location for Medip, MSP and bisulfite sequencing assay. Bar arrow represents 1 κB region on the genome. TSS
represents transcription starting site. B) Analysis of DNA methylation status of 7 TNFRSF members promoter CpG
islands in 5 MM cell lines. Methylated DNAimmunoprecipitation assay was performed to profile promoter
methylation status. Promoter of housekeeping gene GAPDH was used as unmethylated control. Fold enrichment
was calculated as described in the method and normalized to GAPDH. C) Bisulfite sequencing at the CpG island of
GITR promoter, with circles denoting the methylation status of each selected clone. Black and white circles are
methylated CG dinucleotides, and non-methylated CpG dinucleotides and TG dinucleotides, respectively. D) Re-
expression of GITR mRNA level was examined by real-time PCR in the presence of 5’ azacytidine (5 µM) for 4 days.
Total RNA was extracted and reverse transcripted with oligo_dT. The mRNA level of GITR was normalized to 18s.
Mean±SD. E) Expression of GITR was determined in 5 MM cell lines by real-time PCR. The mRNA level was
normalized to 18s. Mean±SD. DNA methylation status of GITR in 5 MM cell lines was calculated by counting the
methylated CG sites in the promoter of GITR and divided by total CG number. F) Expression of GITR examined in 9
primary MM and 11 normal bone marrow by tissue array using anti-human GITR monoclonal antibody. 4 slides of
each group were shown. GITR expression was represented as brown color. Staining of tonsil for GITR staining was
considered as positive control.
doi: 10.1371/journal.pone.0066982.g001
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Expression of GFP was measured by flow cytometry
(Figure S4a). We found that the GITR+/GFP+ cells
exhibited a competitive disadvantage compared to
GITR-/GFP+ cells in MM1.S, OPM1 cell lines, indicating
that expression of GITR could lead to increased
cytotoxicity of MM cells (Figure 3a). Cell proliferation
Figure 2.  Expression of GITR correlates with MM clinical pathogenesis.  A) Expression of GITR was
evaluated by Gene expression profiling analysis (GEO 2658 datestes). The average of GITR expression in MG, US
and smoldering MM was labeled as red bar. B) Expression of GITR was evaluated by Gene expression profiling
analysis (GEO 2658 datestes). The average of GITR expression in every MM subtype was labeled as red bar. >C)
Patients belonging to Total Therapy 2 (TT2) and Total Therapy 3 (TT3) trials with available gene expression data
were divided in poor and good prognosis groups based on the 70-gene index generated by the University of
Arkansas for Medical Sciences (UAMS). The cutoffs for the poor prognosis groups were 0.66 and 0.79 for TT2 and
TT3, respectively. Median normalized TNFRSF18 expression level was compared between good and poor prognosis
groups. D) Kaplan-Meier curve showing survival of 414 MM patients in GITR high and GITR low groups. The two
groups were divided by the median of GITR expression in GEP datasets (GSE2658 and GSE5900) and analyzed by
graphpad software (P=0.03).
doi: 10.1371/journal.pone.0066982.g002
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was next evaluated in GITR expressing MM1.S cells
(GITR+), compared to control cells (GITR-); we showed
that inhibition of proliferation was observed in GITR-
overexpressing cells (Figure 3b). We next evaluated
how GITR loss of function would affect proliferation of
MM cells that present with higher GITR levels, such as
RPMI8226 cells; and demonstrated that reduced
expression of GITR in RMPI82226 cells led to increased
cell proliferation (Figure 3c). GITR knockdown efficiency
in RPMI8226 cells has been determined by real-time
PCR (Figure S4b). Due to the importance of neo-
angiogenesis to support MM disease progression and
due to the presence of GITR specific ligand (GITRL) [15]
on the surface of endothelial cells (HUVECs), we next
investigated the role of GITR in MM cells in the
presence of endothelial cells. In vitro co-culture of
GITR-overexpressing MM1.S with HUVECs led to
significant inhibition of cell growth, thus providing a
further evidence of the tumor suppressor role of GITR
in MM (Figure S4c).
We next validated our in vitro findings by using an in
vivo xenograft MM mouse model. GITR expression was
enhanced in MM1.S cells by using lentiviral vector.
5x106 GITR+ MM1.S cells and GITR-empty vector
infected control MM1.S cell were injected into SCID-bg
mice via tail vein respectively. After 4 weeks, bone
marrow tissues were extracted from both control and
experimental mice groups. We observed significant
reduction of growth of MM cells in mice that received
GITR-overexpressing cells, compared to control groups,
suggesting that GITR is a critical regulator of tumor
growth in MM cells both in vitro and in vivo (Figure
3d-3e). Taken together, these studies suggest that
GITR acts as a potential tumor suppressor in MM.
GITR induces expression of p21 and PUMA in a
ligand dependent manner
To understand the molecular basis of the role of GITR
as a potential tumor suppressor in MM, we analyzed
the specific gene expression signature in GITR
overexpressing cells compared to cells transfected with
empty vector. Gene annotation analysis showed that
the p53 signaling pathway represents the most
significantly enriched gene set, (P<0.001), together
with up-regulation of MDM2, CDKN1a (p21), E2F1, Fas,
IGF-BP3 and CD82 genes (Table. S1). Meanwhile,
apoptosis response genes including Tumor Necrosis
Factor Receptor Type 1-Associated Death Domain
protein (TRADD) and Death Associated Protein (DAP)
were also upregulated in GITR-overexpressing MM cells.
Expression of these genes was validated in both GITR+
MM1.S and GITR knockdown RPMI8226 cells by real
time PCR; showing overexpression of GITR could
increase the level of p21, Fas, TRADD and DAP, in
contrast knockdown of GITR could lead to decreased
mRNA level of these genes (Figure S5a). Based on
these results, we examined the expression of p53 in
MM cells in response to stimulation with GITRL using
qRT-PCR and western blot. We found that expression of
GITR could lead to both increased mRNA and protein
level of p53 in 12hrs after stimulation with 10ng/ml
GITRL (Figure 4a). The elevated p53 protein could
subsequently lead to the induction of p21, which is
another downstream target of p53 and a regulator of
mitochondrial-mediated apoptosis (Figure 4b, and
Figure S5b). Next, we evaluated whether elevated
levels of p21and puma proteins could affect MM cell
cycle progression or apoptosis. We demonstrated that
GITR expressing cells presented with increased
numbers of cells in subG1/G1 phase, together with S
and G2 phase inhibition (Figure 4c). Induction of
apoptosis by GITR expression was also confirmed using
flow cytometry with PI/Annexin V dual staining
combined with immunoblotting for caspase cleavage in
the presence of GITRL (Figure 4d-e). Our results
indicate that GITR could modulate p53-mediated p21
and puma expression, thus mediating cell cycle
progression and apoptosis in MM cells.
GITR negatively regulates NF-κB pathway in
MM cells
NF-κB transcription factors play a key role in the
survival and proliferation of several hematologic
malignancies, including MM [16]. It has been shown
that GITR may negatively regulate NK cell activation
through suppression of the NF-κB pathway [13]. We
therefore dissected the role of GITR in modulating the
canonical NF-κB pathway in both GITR- and GITR+ cell
lines. Cells were exposed to TNF-α (10ng/mL) and
nuclear DNA binding activity and p50/p65 units was
studied by using DNA binding ELISA assay and
immunoblot at 0,15, 30 and 60 minutes. We showed
that TNF-α was able to activate NF-κB pathway in both
control and GITR expressing groups at 15 min (Figure
5a). However, NF-κB activation was abolished at early
30 to 60 min in GITR+ cells after the stimulation,
whereas the NF-κB signal remained elevated up to 60
min in the GITR-cells, suggesting a role of GITR in
terminating TNF-α-induced NF-κB activation (Figure
5a). In addition, we also demonstrated inhibition of
TNF-α-dependent p50 nuclear translocation in GITR+
cells, as shown by immunofluorescence (Figure 5b).
Previous studies showed that IKK-β represents a critical
upstream regulator of P65/p50 activation [17]; we
therefore examined the phosphorylation of IKK-β
stimulated by TNF-α by immunoblotting. Consistently,
the phosphorylation of IKK-β was markedly diminished
by the increased expression of GITR at early time
points. IΚB-α-degradation was also measured in TNF-α
stimulated control and GITR overexpressing cells. We
found that IΚB-α protein decreased back to the basal
level at 30 to 60 min time points in GITR expressing
MM1.S cells, suggesting that TNF-α stimulated NF-κB
activation is IΚB-α-dependent (Figure 5c).
To further confirm that GITR induces inhibition of
TNF-α-induced NF-κB signaling, we evaluated the
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Figure 3.  Effect of GITR on MM tumor proliferation in vitro and in vivo.  A) MM cells (MM.1S and OPM1)
were transfected with PCDH empty and PCDH-GITR with GFP labeled lentiviral vector (Cat# CD511B-1, SBI Inc.)
respectively. Cell proliferation has been evaluated by using GFP competition assay. Expression of GFP and GITR has
been examined by flow cytometry by using anti-human GITR PE labeled primary antobidy. GFP+ and GFP-MM cell
were sorted by BD laser II flow machine. Ratio of GFP+/GFP-was recorded everyday after combination. B) Effect of
GITR-overexpression on MM1.S cell line proliferation. 96 wells plate coated with MM1.S cells were read after 48 and
72 hours respectively. Anti-Brdu-pod was used to detect the absorbance. Mean±SD. *, P<0.05. C) Effect GITR-
knockdown on RPMI.8226 cell line proliferation (RPMI.8226). 96 wells plate coated with MM1.S cells were read after
48 and 72 hours respectively. Anti-Brdu-pod was used to detect the absorbance. Mean±SD. *, P<0.05. D) SCID mice
were injected i.v. with 5 million MM1.S cells, transfected with either empty vector (contrl C1, C2) or GITR (GITR+,
G1, G2). In vivo tumor progression has been evaluated by using immunofluorescence staining with anti-human
CD138 monoclonal antibody after 4 weeks injection, on bone marrow femurs. E) Detection of MM cells from tissues
of mice injected with either empty vector (control) or GITR (GITR+). MM cells have been detected by using flow
cytometry analysis for CD138. Mean±SD. *, P<0.05; **, P<0.01.
doi: 10.1371/journal.pone.0066982.g003
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Figure 4.  GITR induces up-regulation of p21 and PUMA in MM cells.  A) Total protein and RNA was
extracted in 0, 3, 6, 12, 24 and 48 hours after treatment with GITRL (10ng/mL) from GITR- and GITR+ MM1.S cells.
Both Protein and mRNA level of p53 have been evaluated by western blot and qRT-PCR. Actin was considered as
the protein loading control. CT value of qRT-PCR was normalization to 18s. Mean ±SD. B) GITR- and GITR+ cells
were exposed to GITR-L (0-5-10ng/mL) for 24 hrs. whole cellular protein was extracted and subjected to Western
blot using anti-p21, -PUMA and -actin antibodies. C) GITR- and GITR+ MM1.S cells were exposed to GITR-L (5-10
ng/mL) for 24 hours respectively. Cell cycle has been evaluated by using PI staining and flow cytometry analysis. D)
GITR- and GITR+ MM1.S cells were exposed to GITR-L (5-10ng/mL) for 24 hours. Whole protein lysates have been
subjected to Western blot using anti-caspase-3, 9 and –tubuilin antibodies. E) GITR- and GITR+ MM1.S cells were
exposed to GITR-L (5-10ng/mL) for 24 hours. Cells were stained by PI/Annexin V to evaluate apoptosis effect using
flow cytometry. Mean ±SD.
doi: 10.1371/journal.pone.0066982.g004
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Figure 5.  Effect of GITR on canonical NF-κB pathway.  A) Effect of GITR on TNF-α induced NF-κB activation.
NF-κB activity has been evaluated by using DNA binding ELISA assay in GITR- and GITR+ MM1.S cells. Cells were
exposed to TNF-α (10ng/mL) for 15-30-60 minutes. NF-κB p65 and p50 transcription factor binding to its consensus
sequence on the plate-bound oligo nucleotide was examined from nuclear extracts. Data represent mean plus or
minus SD of triplicate experiments. Nuclear protein lysates were also subjected to Western blot using anti-p50, -p65
and -nucleolin antibodies. B) GITR- and GITR+ were harvested at 24 hours after treatment with and without TNF-α
(10 ng/mL) for 60 minutes; Immunocytochemical analysis was assessed using anti-phospho-NF-κB-p50 antibody,
with DAPI used to stain nuclei. C) GITR- and GITR+ cells were exposed to TNF-α (10ng/mL) for 15-30-60 minutes.
Whole cellular protein lysates have been subjected to Western blot using anti-p65, -phospho(p)-IκB beta, -IκB beta,
-IκB alpha, and -actin antibodies. D) GITR- and GITR+ cells were exposed to TNF-α (2.5-5-10ng/mL) for 16 hours.
Whole cellular protein lysates have been subjected to Western blot using anti-BCL-2, -survivin and -actin antibodies.
E) GITR- and GITR+ cells were exposed to TNF-α (2.5-10ng/mL) for 12 hours. Apoptosis was evaluated by Annexin/PI
staining and flow cytometry analysis. Mean±SD.
doi: 10.1371/journal.pone.0066982.g005
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expression p65/p50-downstream targets, such as BCL-2
and survivin. As demonstrated at protein level, BCL2
and survivin expression was upregulated in GITR-MM
cells, upon stimulation with TNF-α. In contrast, no
significant changes of BCL-2 and survivin were
observed in GITR overexpressing cells in response to
TNF-α (Figure 5d).
Previous studies showed that TNF-α alone may be
responsible for NF-κB nuclear translocation, cIAP-1 and
cIAP-2 up-regulation, thus leading to increase in MM
cell proliferation [18]. To explore the effect of GITR on
apoptosis induced by TNF-α in MM cells, we performed
PI/Annexin dual staining assay. We found that GITR was
able to counteract NF-κB mediated anti-apoptosis
signals and facilitate the apoptosis induced by TNF-α in
GITR expressing MM cells (Figure 5e). Taken together,
these findings further support our hypothesis that GITR
negatively regulates canonical NF-κB pathway
activation by inhibiting phosphorylation of IKK-β in MM
cells at early time points.
Discussion
MM is a plasma cell neoplasia characterized by
activation of the NF-κB pathway through cell
autonomous mutations or external signaling from the
tumor microenvironment [19,20]. In this study, we
demonstrated that epigenetic silencing of GITR is
involved in MM cell proliferation, is associated with an
anti-apoptosis effect and is contributing to NF-κB-
mediated MM pathogenesis. Notably, using bisulfite
sequencing, we observed that all of the methylated
cytosines are distributed at the first 130 base pair of
promoter CGI region in both MM cell lines and primary
bone marrow CD138+ MM cells, suggesting that the
aberrant methylation of GITR promoter in MM cells is
not a random epigenetic event. To link the function of
GITR to MM cell behavior, we sought to investigate if
the expression of GITR correlates with MM cells
proliferation. Indeed, we demonstrated that expression
of GITR could inhibit MM cells proliferation in vitro and
in vivo. These results indicate that GITR acts as a
potential tumor suppressor gene on MM cells and we
confirmed that its re-expression induces apoptosis in
MM cells. These results are consistent with previous
reports indicating that deletion of GITR could lead to
increased proliferation in T lymphocytes [21].
GITR is located on chromosome 1p36. Deletion of
1p36 is associated with increased risk for neoplasia,
including neuroblastoma, prostate cancer, lung cancer,
melanoma and non-Hodgkin lymphomas [22–27]. It has
been previously shown that heterozygous deletions at
1p36 were also found in 8% of MM patients, indicating
that this region may contain putative tumor suppressor
genes [28]. We analyzed published aCGH data from
238 MM patients and 60 human myeloma cell lines and
found that about 8% MM patients have monoallelic
deletion of 1p, which is consistent with the previous
reports. The DNA methylation-mediated loss of GITR in
MM may also provide evidence of alternative
contribution of 1p36 abnormality to MM tumorigenesis.
Recent studies in Chronic Lymphocytic Leukemia
(CLL) have shown pronounced expression of GITRL and
the GITR receptor was expressed at significantly higher
levels on NK cells of CLL patients compared with
healthy controls. In addition, GITRL contributed to
resistance of CLL cells to rituximab therapy, indicating
that GITR/GITRL contributes to disease progression and
resistance to Rituximab-induced NK reactivity in CLL
[29]. In another study, constitutive expression of GITRL
by tumor cells diminished NK cell antitumor immunity
[30]. Moreover, in GITR-/- mouse models, the lack of
expression of GITR was shown to modestly contribute
to mature B cell homeostasis [31]. Our study
demonstrated that the tumor suppressor properties of
GITR are characterized by inhibition of proliferation and
induction of apoptosis as well as induction of
downstream targets of p53, such as p21, MDM2, Fas,
IGF-BP3 and CD82. This data support the presence of a
putative crosstalk between GITR and the p53 pathway.
Therefore we attempted to elucidate the molecular
basis that link p53 signal to the GITR pathway. We
observed significantly increased p53 level in GITR+,
leading to induction of p21 and puma in MM cells in
response to GITRL. Further studies are needed to better
define the interaction between GITR and the p53-
related signaling cascade.
NF-κB transcription factors play a key role in the
survival and proliferation of plasma cell malignancies,
including multiple myeloma [32–34]. It was shown that
mutations involved in the NF-κB pathway are present in
at least 17% of MM tumors and 40% of MM cell lines
[35–37]. These mutations can lead to activation of the
canonical NF-κB pathway via modulating the level of
NIK, TRAFs and CD40. Therefore, targeting the NF-κB
pathway is an attractive therapy for MM [20,38]. Our
data indicates that GITR negatively regulates the
canonical NF-κB pathway by terminating the canonical
NF-κB activation as early as 30 minutes post-
stimulation with TNF-α. The inhibitory role of GITR in
the NF-κB pathway was further supported by inhibition
of phosphorylation of IKK-β and protection of
degradation of IκB. We speculate that this effect could
possibly result from either binding of TNF-α to GITR or
blocking the intracellular cell signaling transduction of
TNF-α by GITR (Figure 6). Further elucidation of GITR
mediated disruption of the NF-κB pathway will be
critical for understanding the role of GITR in the
pathogenesis of MM and the development of future
therapeutic agents.
Overall, our results demonstrate that GITR acts as a
potential tumor suppressor in MM. Furthermore, our
data links GITR to p53-associated modulation of p21
and puma in myeloma cells. Most importantly, our
findings reveal an inhibitory role of GITR in regulating
NF-κB pathway, providing a novel insight into the role
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of TNFRSFs family in MM pathogenesis and disease
progression, thus supporting the therapeutic use of NF-
κB inhibitors in MM patients who present with increased
GITR methylation.
Supporting Information
Figure S1.  Deregulation of TNFRSFS in multiple
myeloma.  A) Expression of TNFRSFs member was
assessed by analyzing GEO dataset GSE2658.
Expression value was used to calculate the p-value by
T-test. The heat map was generated for all of the
TNFRSFs members. Significance of differential
expression of TNFRSFs members, which were selected
according to the p-value(<0.05), is shown by the
intensity of red (up-regulation) versus blue (down-
regulation).
Figure S2.  Hypermethylation of GITR in MM
cells.  A) Loss of methylation enrichment of GITR
promoter in the presence of demethylation agent 5’
azacytidine in MM cell line by meDIP assay. Fold
enrichment was normalized to GAPDH. B) Methylation
specific PCR was performed to evaluated the
methylation status of primers MM cells from 5 patients.
According to the BSP results, MM1.S were considered
as positive control and ddH2O as negative control. C)
DNA sequencing was done in primary MM DNA samples
after bisulfate convertion followed by subcloning into T-
easy vector. C > T represents unmethylated C,
whereas C>C represents methylated C. D) expression
of GITR mRNA level was examined by real-time PCR in
the presence of 5’ azacytidine (5 µM) for 4 days. Total
RNA was extracted and reverse transcripted with
oligo_dT from INA6, U266 and RPMI8226 cell lines. The
mRNA level of GITR was normalized to 18s. Mean ±SD.
Figure 6.  GITR inhibits NF-κB pathway.  A proposed model to summarize the ability of GITR to modulate TNF-α
induced canonical NF-κB pathway. The presence of GITR in MM cells could disrupt TNF-α/TNFR induced NF-κB
activation by blocking phosphorylation of IKK-beta, subsequenctly leading to early termination of nuclear
translocation of NF-κB p65/p50 and impaired induction of BCL-2 and Survivin.
doi: 10.1371/journal.pone.0066982.g006
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Figure S3.  Promoter DNA methylation leads to
GITR silencing in MM cells.  Re-expression of GITR
protein level was determined by flow cytometry
exposed to 5’ azacytidine in a dose depedent manner.
Cells were harvested after 96 hrs of incubation with 5’
azacytidine and stained with anti-GITR-PE labeled
antibody.
Figure S4.  Expression of GITR affects MM cell
proliferation.  A) MM.1S cells have been transfected
with either empty vector (contrl) or GITR (GITR+).
Expression of GITR has been evaluated by flow
cytometry. Anti-GITR-PE conjugated antibody has been
used. B) Knockdown of GITR in RPMI8226 cell lines by
siRNA was measured by real-time PCR. mRNA level was
normalized to 18s. C) MM cells have been transfected
with either empty vector (contrl) or GITR (GITR+) and
cultured in presence or absence of HUVECs for 48
hours. Cell proliferation has been evaluated by BrdU
assay. Mean ±SD.
Figure S5.  Overexpression of GITR induced the
expression of p21 and puma in a ligand
dependent way.  F) MM1.S cells were transfected
with both GITR overexpressing vector (GITR+) and
empty control vector (GITR-) respectively. RPMI8226
cells were transfected with si-scramble and pooled si-
GITR oligo. Total RNA was extracted in 24 hours after
the transfection. Expression of p21, TRADD, Fas and
DAP has been evaluated by qRT-PCR, with
normalization to 18s. Mean ±SD. G) MM cells were
transfected with either empty vector (contrl) or GITR
(GITR+). Total RNA was extracted in 12 hours after
treatment with GITRL (5-10ng/mL). Expression of p21
and puma was evaluated by qRT-PCR, with
normalization to 18s. Mean ±SD.
Table S1.  Overxpression of GITR is associated
with p53 pathway.  Genes involved in p53 pathway
are shown (cut off = 2 fold, p<0.05).
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